Design of pediatric oral formulations with a low proportion of methadone or phenobarbital for the treatment of neonatal abstinence syndrome

References

• Unger A, Metz V, Fischer G. Opioid dependent and pregnant: what are the best options for mothers and neonates? Obstet Gynecol Int 2012;2012:1–6
   Google Scholar
• Gaalema DE, Heil SH, Badger GJ, et al. Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone. Drug Alcohol Depend 2013;133:266–269
   PubMed Web of Science ®Google Scholar
• Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009;5:47–55
   PubMedGoogle Scholar
• D'Apolito K. Neonatal opiate withdrawal: pharmacologic management. Newborn Infant Nurs Rev 2009;9:62–69
   Google Scholar
• Johnson K, Gerada C, Greenough A. Treatment of neonatal abstinence syndrome. Arch Dis Child 2003;88:2–5
   Web of Science ®Google Scholar
• Wouldes TA, Woodward LJ. Maternal methadone dose during pregnancy and infant clinical outcome. Neurotoxicol Teratol 2010;32:406–413
   PubMed Web of Science ®Google Scholar
• Ebner N, Rohrmeister K, Winklbaur B, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007;87:131–138
   PubMed Web of Science ®Google Scholar
• Hudak ML, Tan RC. The commitee on drugs and the commitee on fetus and newborn. Neonatal drug withrawal. Pediatrics 2012;129:e540–e560
   PubMed Web of Science ®Google Scholar
• O’Grady MJ, Hopewell J, White MJ. Management of neonatal abstinence syndrome: a national survey and review of practice. Arch Dis Child 2009;94:F249–F252
   PubMed Web of Science ®Google Scholar
• Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol 2006;26:15–17
   PubMed Web of Science ®Google Scholar
• Bio LL. Siu A, Poon CY. Update on the pharmacologic management of neonatal abstinence syndrome. J Perinatol 2011;31:692–701
   PubMed Web of Science ®Google Scholar
• Ali AA, Charoo NA, Abdallah DB. Pediatric drug development: formulation considerations. Drug Dev Ind Pharm 2014;40:1283–1299
   PubMed Web of Science ®Google Scholar
• Pal V, Nahata M. Need for extemporaneous formulations in pediatric patients. J Pediatr Pharmacol Ther 2001;6:107–119
   Google Scholar
• Santoveña A, Hernández-Paiz Z, Fariña JB. Design of a pediatric oral formulation with a low proportion of hydrochlorothiazide. Int J Pharm 2012;423:360–364
   PubMed Web of Science ®Google Scholar
• Provenza N, Calpena AC, Mallandrich M, et al. Design and physicochemical stability studies of paediatric oral formulations of sildenafil. Int J Pharm 2014;460:234–239
   PubMed Web of Science ®Google Scholar
• Brion F, Nunn AJ, Rieutord A. Extemporaneous (magistral) preparation of oral medicines for children in European Hospitals. Acta Paediatr 2003;92:486–490
   PubMed Web of Science ®Google Scholar
• Monteagudo E, Langenheim M, Salerno C, et al. Pharmaceutical optimization of lipid-based dosage forms for the improvement of taste-masking, chemical stability and solubilizing capacity of phenobarbital. Drug Dev Ind Pharm 2014;40:783–792
   PubMed Web of Science ®Google Scholar
• Jelveghari M, Nokhodchi A. Development and chemical stability studies of alcohol-free phenobarbital solution for use in pediatrics: a technical note. AAPS PharmSciTech 2008;9:939–943
   PubMed Web of Science ®Google Scholar
• Lauriault G, LeBelle MJ, Lodge BA, Savard C. Stability of methadone in four vehicles for oral administration. Am J Hosp Pharm 1991;48:1252–1256
   PubMedGoogle Scholar
• Soy D, Roca M, Deulofeu R, et al. Estabilidad de las soluciones orales de clorhidrato de metadona al 0.1% y 0.5% en suero fisiológico. Farm Hosp 1998;22:249–251
   Google Scholar
• Denson DD, Crews JC, Grummich KW, et al. Stability of methadone hydrochloride in 0.9% sodium chloride injection in single-dose plastic containers. Am J Hosp Pharm 1991;48:515–517
   PubMedGoogle Scholar
• Tønnesen HH. Formulation and stability testing of photolabile drugs. Int J Pharm 2001;225:1–2
   PubMed Web of Science ®Google Scholar
• ICH Harmonized Tripartite Guideline. Validation of analytical procedures: text and methodology Q2 (R1). Available at: http://www.ema.europa.eu [last accessed 5 Apr 2015]
   Google Scholar
• Araujo J, Garcia ML, Mallandrich M, et al. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomedicine 2010;8:1034–1041
   Web of Science ®Google Scholar
• Jenke DR. Chromatographic method validation: a review of current practices and procedures. II. Guidelines for primary validation parameters. J Liq Chrom Relat Tech 1996;19:737–757
   Web of Science ®Google Scholar
• Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165–175
   PubMedGoogle Scholar
• European Pharmacopoeia. Microbiological quality of non-sterile products for pharmaceutical use. 7th ed. Strasbourg: Council of Europe; 2010:519–520
   Google Scholar
• Lee CH, Moturi V, Lee E. Thixotropic property in pharmaceutical formulations. J Control Release 2009;136:88–98
   PubMed Web of Science ®Google Scholar
• Schellart WP. Rheology and density of glucose syrup and honey: determining their suitability for usage in analogue and fluid dynamic models of geological processes. J Struct Geol 2011;33:1079–1088
   Web of Science ®Google Scholar
• James A. The legal and clinical implications of crushing tablet medication. Nurs Times 2005;100:28–29
   Google Scholar
• Ferry AL, Hort J, Mitchell JR, et al. Viscosity and flavour perception: why is starch different from hydrocolloids? Food Hydrocolloids 2006;20:855–862
   Web of Science ®Google Scholar
• Martin A. Physical pharmacy. Philadelphia (PA): Lea & Febiger; 1993
   Google Scholar
• Ofner CM, Schnaare RL, Schwartz JB. Reconstitutable oral suspensions. In: Lieberman HA, Rieger MM, Banker GS, eds. Pharmaceutical dosage forms: disperses systems. New York: Marcel Dekker, Inc.; 1996:247–9
   Google Scholar
• Benchabane A, Bekkour K. Rheological properties of carboxymethyl cellulose (CMC) solutions. Colloid Polym Sci 2008;286:1173–1180
   Web of Science ®Google Scholar
• Schmidt D, Kupferberg J. Diphenylhydantoin, phenobarbital, and primidone in saliva, plasma, and cerebrospinal fluid. Epilepsia 1975;16:735–741
   PubMed Web of Science ®Google Scholar